TOSHIBA/UT-FORTEM
22.3.2021 23:02:06 CET | Business Wire | Press release
Toshiba Corporation (TOKYO:6502) today announced that Toshiba Infrastructure Systems & Solutions Corporation, the Toshiba Group company specializing in the global infrastructure business (hereinafter Toshiba), has entered into a strategic business alliance with Fortem Technologies, Inc. (hereafter Fortem), and invested 15 million USD in the company. Fortem is a technology leader in counter-drone security and Toshiba, through the alliance, aims to expand its radar-based security solutions business.
Based in Utah, US, Fortem is a drone security company that has grown rapidly in recent years by supplying leading counter-drone systems, notably highly accurate small drone detection radars that are easily installed, and autonomous drones that can capture rogue drones in a net.
“Toshiba is a world-renowned technical and sales powerhouse,” said Timothy Bean, CEO of Fortem. “We are very pleased to announce this alliance to accelerate the delivery of solutions to our customers that combine the disruptive innovation of our AI-enabled Fortem SkyDome System with the depth of Toshiba’s commercial drone RF detection expertise and advanced radar technology. This partnership brings added confidence to security professionals who must secure the airspace above their venues, campuses and metro regions.”
Toshiba has already commercialized a drone detection system that plots incoming direction and altitude from radio waves emitted by the drone in flight. Toshiba is also strengthening its drone security business through research and development of related products.
The alliance will integrate Toshiba and Fortem’s highly complementary systems to realize more effective, multi-layered counter-drone solutions and services, and expand sales in Japan and the US, and in promising overseas markets, including those of Asia, Europe, the Middle East, with mutual access to each other’s sales network.
Masaki Haruyama, Vice President of Toshiba said, “We are excited to partner with Fortem, a pioneering counter-drone solution provider with proven detection system and unique and highly effective interception system. Toshiba has a long history of providing leading technologies of radars. With the perfectly complementary technologies and products of the two companies, we are confident that we can become a global top-tier player in a rapidly growing market, and contribute a safer, more reliable facilities.
Going forward, Toshiba will contribute to ensuring infrastructure security through the alliance with Fortem, by responding to the growing need to prevent damage caused by suspicious drones at airports and other critical facilities, stadiums and other large venues, and private properties around the world. Toshiba aims to win annual sales of 30 billion JPY in the counter-drone security business by FY2030.
About Fortem Technologies, Inc.
- Founded: 2016
- Representative: Timothy Bean
- Headquarters: Utah, the United States
- Employees: Over 100 people
- Business: Counter-drone security products and services
About Toshiba Corporation
Toshiba Corporation leads a global group of companies that combines knowledge and capabilities from over 140 years of experience in a wide range of businesses—from energy and social infrastructure to electronic devices—with world-class capabilities in information processing, digital and AI technologies. These distinctive strengths support Toshiba’s continued evolution toward becoming an Infrastructure Services Company that promotes data utilization and digitization, and one of the world’s leading cyber-physical-systems technology companies. Guided by the Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future,” Toshiba contributes to society’s positive development with services and solutions that lead to a better world. The Group and its 130,000 employees worldwide secured annual sales surpassing 3.4 trillion yen in FY2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210322005284/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom